nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2020-3-82-86nnp-1363Research ArticleORIGINAL INVESTIGATIONSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИThe first experience with Angiovit in the combination treatment of acute COVID-19 infectionПервый опыт использования препарата Ангиовит в комплексном лечении острой стадии инфекции COVID-19БойкоА. Н.BoykoA. N.

Бойко Алексей Николаевич.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10.

Aleksey Nikolaevich Boyko.

Ostrovityanov St., Moscow 117997; 1, Ostrovityanov St., Build. 10, Moscow 117997.

boykoan13@gmail.comШамаловН. А.ShamalovN. A.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10.

11, Ostrovityanov St., Moscow 117997; 1, Ostrovityanov St., Build. 10, Moscow 117997.

БойкоО. В.BoykoO. V.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10.

11, Ostrovityanov St., Moscow 117997; 1, Ostrovityanov St., Build. 10, Moscow 117997.

АрининаЕ. Е.ArininaE. E.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10.

ЛянгО. В.LyangO. V.

117997, Москва, ул. Островитянова, 1, стр. 10.

ДубченкоЕ. А.DubchenkoE. A.

117997, Москва, ул. Островитянова, 1, стр. 10.

ИвановА. В.IvanovA. V.

125315, Москва, Балтийская ул., 8.

8; Baltiyskaya St., Moscow 125315.

КубатиевА. А.KubatievA. A.

125315, Москва, Балтийская ул., 8.

8; Baltiyskaya St., Moscow 125315.

Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России; отдел нейроиммунологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБАРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for the Brain and Neurotechnologies, Federal Biomedical AgencyRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России; отдел нейроиммунологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБАРоссияDepartment of Neuroimmunology, Federal Center for the Brain and Neurotechnologies, Federal Biomedical AgencyRussian FederationОтдел нейроиммунологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБАРоссияDepartment of Neuroimmunology, Federal Center for the Brain and Neurotechnologies, Federal Biomedical AgencyRussian FederationНаучно-исследовательский институт общей патологии и патофизиологииРоссияResearch Institute of General Pathology and PathophysiologyRussian Federation2020250620201238286Copyright © Boyko A.N., Shamalov N.A., Boyko O.V., Arinina E.E., Lyang O.V., Dubchenko E.A., Ivanov A.V., Kubatiev A.A., 20202020Бойко А.Н., Шамалов Н.А., Бойко О.В., Аринина Е.Е., Лянг О.В., Дубченко Е.А., Иванов А.В., Кубатиев А.А.Boyko A.N., Shamalov N.A., Boyko O.V., Arinina E.E., Lyang O.V., Dubchenko E.A., Ivanov A.V., Kubatiev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1363

On March 11, 2020, the WHO announced the COVID-19 outbreak a pandemic. The disease was established to be caused by a new singlestranded RNA virus (ss-RNA, 29903 bp) that belongs to a group of coronaviruses (CoV).

Objective

Objective: to assess the results of a pilot analysis of the efficiency of using Angiovit in the combination treatment of acute COVID-19 with pneumonia or acute respiratory viral infection.

Patients and methods

Patients and methods. The study enrolled 50 patients with acute COVID-19. In all the patients, the diagnosis of coronavirus infection was confirmed by polymerase chain reaction. Angiovit was used in 25 patients (13 (52%) women) (mean age, 39.4 years) with moderate infection who had been admitted on an average of disease day 3 (a study group). A comparison group consisted of 25 patients whose gender, age, and clinical features of COVID-19 did not differ at the time of admission; they were prescribed only mainstay therapy.

Results and discussion

Results and discussion. Adding Angiovit to the mainstay therapy contributed to an average reduction in the fever period from 5.88 to 4.12 days (p<0.05) and to the earlier hospital discharge of patients with an improvement (on day 13 versus on day 16.8 days in the comparison group; p<0.05); Normalization of CRP, D-dimer, and homocysteine levels occurred considerably and faster.

Conclusion

Conclusion. The pilot study has shown that the use of Angiovit in the combination therapy of COVID-19 reduces the clinical and laboratory manifestations of inflammation and hypercoagulation, which may also be associated with the action of folic acid.

11 марта 2020 г

11 марта 2020 г. ВОЗ объявила о пандемии инфекции COVID-19. Было установлено, что заболевание вызвано новым одноцепочечным РНК-вирусом (ss-RNA, 29903 bp), относящимся к группе коронавирусов (CoV).

Цель исследования — оценка результатов пилотного анализа эффективности использования препарата Ангиовит в комплексном лечении острой стадии инфекции COVID-19 с пневмонией или острой респираторной вирусной инфекцией.

Пациенты и методы

Пациенты и методы. В исследование включено 50 больных с острой стаДией COVID-19-инфекции. У всех больных диагноз коронавирусной инфекции подтвержден с помощью полимеразной цепной реакции. Препарат Ангиовит получали 25 пациентов со средней тяжестью инфекции (женщин 13; 52%), средний возраст — 39,4 года, которые поступили в среднем на 3-й день заболевания (основная группа). Группу сравнения составили 25 пациентов, не отличавшихся по полу, возрасту и особенностям клинических проявлений инфекции COVID-19 на момент поступления, которым назначали только базовую терапию.

Результаты и обсуждение

Результаты и обсуждение. Добавление к базовой терапии препарата Ангиовит способствовало уменьшению периода лихорадки в среднем с 5,88 до 4,12 дня (p<0,05), а также более ранней выписке пациентов из стационара с улучшением (на 13-й День по сравнению с 16,8 Дня в группе сравнения; p<0,05); значимо и быстрее нормализовались уровни СРБ, D-димера и гомоцистеина.

Заключение

Заключение. Как показало пилотное исследование, использование Ангиовита к комплексной терапии при инфекции COVID-19 уменьшает клинико-лабораторные проявления воспаления и гиперкоагуляции, что может быть связано в том числе с действием фолиевой кислоты.

COVID-19лечениеАнгиовитфолиевая кислотаCOVID-19treatmentAngiitisfolic acidReferenceshttps://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020https://www.cdc.gov/coronavirus/types.htmlhttps://www.cdc.gov/coronavirus/types.htmlZou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med.2020 Apr;14(2):185-92. doi: 10.1007/s11684-020-0754-0. Epub 2020 Mar 12.Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med.2020 Apr;14(2):185-92. doi: 10.1007/s11684-020-0754-0. Epub 2020 Mar 12.Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020 Apr 27; 10(12):5613-22. doi: 10.7150/thno.45985. eCollection 2020.Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020 Apr 27; 10(12):5613-22. doi: 10.7150/thno.45985. eCollection 2020.Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging (Albany NY). 2020 Apr 10;12(7):6037-48. doi: 10.18632/aging.102999. Epub 2020 Apr 10.Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging (Albany NY). 2020 Apr 10;12(7):6037-48. doi: 10.18632/aging.102999. Epub 2020 Apr 10.Serseg T, Benarous K, Yousfi M. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study. Curr Comput Aided Drug Des. 2020 Apr 21. doi: 10.2174/1573409916666200422075440. Online ahead of print.Serseg T, Benarous K, Yousfi M. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study. Curr Comput Aided Drug Des. 2020 Apr 21. doi: 10.2174/1573409916666200422075440. Online ahead of print.Дубченко ЕА, Иванов АВ, Бойко АН и др. Гипергомоцистеинемия и эндотелиальная дисфункция при сосудистых и аутоиммунных заболеваниях головного мозга. Журнал неврологии и психиатрии им. С.С.Корсакова. 2019;119(11):127-32.Dubchenko EA, Ivanov AV, Boiko AN, et al. Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2019;119(11): 127-32. (In Russ.).https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_MR_COVID-19_v6.pdfhttps://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_MR_COVID-19_v6.pdfBolander-Gouaille C. Focus on Homocysteine and the Vitamins involved in its metabolism. Springer Verlag France; 2002. 217 p.Bolander-Gouaille C. Focus on Homocysteine and the Vitamins involved in its metabolism. Springer Verlag France; 2002. 217 p.Lentz SR, Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med. 2004 Sep;71(9):729-34. doi: 10.3949/ccjm.71.9.729.Lentz SR, Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med. 2004 Sep;71(9):729-34. doi: 10.3949/ccjm.71.9.729.Rasic-Markovic A, Stanojlovic O, Hrncic D, et al. The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administration. Mol Cell Biochem.2009 Jul;327(1-2):39-45. doi: 10.1007/s11010-009-0040-6. Epub 2009 Feb 18.Rasic-Markovic A, Stanojlovic O, Hrncic D, et al. The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administration. Mol Cell Biochem.2009 Jul;327(1-2):39-45. doi: 10.1007/s11010-009-0040-6. Epub 2009 Feb 18.Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulate LOX expression in vascular endothelial cells. Atherosclerosis. 2004 Nov;177(1):1-8. doi: 10.1016/j.atherosclerosis.2004.06.015.Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulate LOX expression in vascular endothelial cells. Atherosclerosis. 2004 Nov;177(1):1-8. doi: 10.1016/j.atherosclerosis.2004.06.015.Sen U, Mishra PK, Tyagi N, Tyagi SC. Homocysteine to Hydrogen Sulfide or Hypertension. Cell Biochem Biophys. 20 1 0 Jul; 57(2-3):49-58. doi: 10.1007/s12013-010-9079-y.Sen U, Mishra PK, Tyagi N, Tyagi SC. Homocysteine to Hydrogen Sulfide or Hypertension. Cell Biochem Biophys. 20 1 0 Jul; 57(2-3):49-58. doi: 10.1007/s12013-010-9079-y.Li JJ, Li Q, Du HP, et al. Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter. Int J Mol Sci.2015 Jun 3;16(6):12560-77. doi: 10.3390/ijms160612560.Li JJ, Li Q, Du HP, et al. Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter. Int J Mol Sci.2015 Jun 3;16(6):12560-77. doi: 10.3390/ijms160612560.Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia. Front Aging Neurosci. 2018 Oct 31;10:350. doi: 10.3389/fnagi.2018.00350. eCollection 2018.Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia. Front Aging Neurosci. 2018 Oct 31;10:350. doi: 10.3389/fnagi.2018.00350. eCollection 2018.Moretti R., Caruso P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. Int J Mol Sci. 2019 Jan 8;20(1):231. doi: 10.3390/ijms20010231.Moretti R., Caruso P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. Int J Mol Sci. 2019 Jan 8;20(1):231. doi: 10.3390/ijms20010231.Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta.2020 Aug; 507:167-73. doi: 10.1016/j.cca.2020.04.027. Epub 2020 Apr 26.Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta.2020 Aug; 507:167-73. doi: 10.1016/j.cca.2020.04.027. Epub 2020 Apr 26.Yao D, Sun NL. Hyperhomocysteinemia accelerates collagen accumulation in the adventitia of balloon-injured rat carotid arteries via angiotensin II type 1 receptor. Int J Mol Sci. 2014 Oct 27;15(11):19487-98. doi: 10.3390/ijms151119487.Yao D, Sun NL. Hyperhomocysteinemia accelerates collagen accumulation in the adventitia of balloon-injured rat carotid arteries via angiotensin II type 1 receptor. Int J Mol Sci. 2014 Oct 27;15(11):19487-98. doi: 10.3390/ijms151119487.Li T, Yu B, Liu Z, et al. Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury. Nat Commun.2018 Jan 2;9(1):11. doi: 10.1038/s41467-017-02401-7.Li T, Yu B, Liu Z, et al. Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury. Nat Commun.2018 Jan 2;9(1):11. doi: 10.1038/s41467-017-02401-7.Shi L, Liu XY, Huang ZG, et al. Endogenous hydrogen sulfide and ERK1/2-STAT3 signaling pathway may participate in the association between homocysteine and hypertension. J Geriatr Cardiol. 2019 Nov;16(11):822-834. doi: 10.11909/j.issn.1671-5411.2019.11.007.Shi L, Liu XY, Huang ZG, et al. Endogenous hydrogen sulfide and ERK1/2-STAT3 signaling pathway may participate in the association between homocysteine and hypertension. J Geriatr Cardiol. 2019 Nov;16(11):822-834. doi: 10.11909/j.issn.1671-5411.2019.11.007.

The authors declare that there are no conflicts of interest present.